WWC
IRWD icon

Waypoint Wealth Counsel’s Ironwood Pharmaceuticals IRWD Stock Holding History

Waypoint Wealth Counsel’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.1K Sell
11,999
-504
-4% -$2.07K 0.02% 225
2025
Q4 		$42.1K Sell
12,503
-155
-1% -$403 0.02% 282
2025
Q3 		$16.6K Buy
+12,658
New +$13.1K 0.01% 267

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Waypoint Wealth Counsel's IRWD Position: Q1 2026 in Review

Waypoint Wealth Counsel reduced its Ironwood Pharmaceuticals (IRWD) stake by 4% in Q1 2026, selling an estimated $2.07K and leaving 11,999 shares worth $42.1K. The position accounts for 0.02% of the portfolio, ranked #225.

Waypoint Wealth Counsel first reported a position in IRWD in Q3 2025 and has held it in 3 quarters since. The position peaked at $42.1K in Q4 2025. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Waypoint Wealth Counsel held 11,999 shares of Ironwood Pharmaceuticals worth $42.1K as of Q1 2026.
  • Waypoint Wealth Counsel sold 504 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $2.07K.
  • Ironwood Pharmaceuticals made up 0.02% of Waypoint Wealth Counsel's portfolio in Q1 2026, its #225 holding.
  • Waypoint Wealth Counsel first reported a position in Ironwood Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Waypoint Wealth Counsel's Ironwood Pharmaceuticals position peaked at $42.1K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q1 2026, filed 23 Apr 2026.